摘要
目的 通过母体乐-375、TCu380A和元宫-365 3种宫内节育器(IUD)的大样本上市后多中心随机对照试验,评价中国妇女使用IUD的安全性和有效性,为我国IUD荐优汰劣提供参考依据.方法 应用多中心随机对照临床试验对24 000例健康已婚育龄妇女进行健康筛查,采用分层区组随机分配3种IUD;在置器后的1~3、6、12个月进行随访,观察IUD的使用终止率.结果 3种IUD 1年的总终止率不同,元宫-365 IUD最低,为4.21%;TCu380A其次,为8.42%;母体乐-375最高,为13.91%(P<0.01);3种IUD 1年的意外妊娠发生率、脱落率、出血终止率和下移取出率均有差异.使用母体乐-375、有不良反应无医学处理、随访次数少、宫腔较深、IUD失败后再次使用是使用终止的高风险因素.结论元宫-365 IUD是发生终止风险最小的IUD种类;规范随访,及时处理不良反应可较大程度地减少发生终止的风险.
: Objective To assess the safety and effectiveness of intrauterine device in Chinese women.Methods In this multicenter randomized controlled trial,a total of 24 000 women were randomly (1∶1∶ 1)into 3 groups of Yuangong Cu 365(YCu365),Copper T 380A(TCu380A)and Multiload Cu 375 (MLCu375).Clinical outcomes were assessed at 12 months post-insertion,including discontinuation due to pregnancy,expulsion,hemorrhage and downward displacement,etc.The overall and causal-specific discontinuation rates for adverse events were calculated.Results At the end of the first year,the discontinuation rate of YCu365(4.21%)was the lowest,followed by TCu380A(8.42%)and MLCu375 (13.91%)(P 〈0.01).The differences of discontinuation rates for pregnancy,expulsion,hemorrhage and downward displacement between these IUDs were also significant.MLCu375,side effect without medical treatment,fewer follow-ups,deeper uterine cavity and previous IUD failure were significantly associated with an increased risk of IUD discontinuation.Conclusion The newly developed indomethacin-releasing YCu365 IUD appears to perform the best.However,its long-term safety and cost-effectiveness should be further evaluated.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2011年第45期3172-3175,共4页
National Medical Journal of China
基金
国家“十五”科技攻关计划课题(2004BA720A32)
国家“十一五”科技支撑计划课题(2006BA115B07).志谢该课题在设计时得到国家人口和计划生育委员会科技司张世琨、张黎明、沈海屏,国家食品药品监督管理局器械司王兰明,WHO Van Look博士、Iqbal shah博士,新西兰药物警戒中心David Coulter博士的指导和帮助
课题现场实施得到江苏省、上海市、广东省、四川省、重庆市、安徽省人口和计划生育委员会的大力支持,同时也得到上述省市的试点县计划生育技术指导站和卫生部门的支持与参与.顾晓萍、孙志明、申素琪、姚婕、陈颖、柏建岭、唐红艳、黄玉、陈诚、赵锦娜等参加随访质量控制和数据整理
关键词
宫内节育器H多中心
随机对照试验
终止率
随访
Intrauterine device(IUD)
Multicentre
Randomized controlled trial(RCT)
Discontinuation rate
Follow up